Buy Biogen

Logo for stock BIIB (Biogen)

Amount

£
GBP

Latest price

$140.32
(£1.00 = $1.242)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$20.771B

P/E ratio

12.88

EPS

$11.063

Beta

0.01

Dividend rate

N/A

Dividend yield

N/A

About

Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.

CEO

Mr. Christopher A. (Chris) Viehbacher

Employees

7,570

Sector

Health

Company HQ

CAMBRIDGE, United States of America

Website

News

Logo for news article #0 (Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?)

Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?

We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.

Zacks Investment Research

February 10, 2025

Logo for news article #1 (Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics)

Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Beyond analysts' top -and-bottom-line estimates for Biogen (BIIB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

Zacks Investment Research

February 07, 2025

Logo for news article #2 (Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth)

Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research

February 05, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies Ltd is an Introducer Appointed Representative of Quint Group Limited, which is authorised and regulated by the Financial Conduct Authority (FRN 669450). Emma Technologies Ltd is not a lender. Emma Technologies Ltd introduces customers to Monevo Limited who is a licensed credit broker.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.